{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:28:55Z","timestamp":1787048935595,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T00:00:00Z","timestamp":1758326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preterm infants who receive caffeine for apnea of prematurity have improved neurodevelopmental outcomes compared to untreated infants. The optimal dosing regimen for neuroprotection is unknown. We hypothesized that higher caffeine exposure is associated with improved neurodevelopmental performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We quantified caffeine exposure in a previously reported cohort of 106 infants born at \u226432 gestational weeks who received brain MRIs during the neonatal hospitalization. Infants were subdivided into tertiles based on average daily caffeine exposure (ADCE). Bayley-III examinations were performed on 69 participants at 30 months corrected age. Neurodevelopmental impairment (NDI) was defined as a score of \u226485 on the Bayley-III motor, language, and\/or cognitive subscales. We evaluated the relationship between caffeine exposure, neuroimaging abnormalities, and neurodevelopmental performance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Higher ADCE was associated with decreased odds of NDI (OR 0.69, 95% C.I. 0.50\u20130.95) but not with MRI abnormalities. High dose caffeine was associated with improved motor (mean difference 10.9, 95% C.I. 0.7\u201321.0), language (mean difference 15.2, 95% C.I. 3.4\u201327.0), and cognitive (mean difference 13.0, 95% C.I. 0.6\u201325.4) performance compared to low dose in multivariable analyses adjusted for gestational age and respiratory disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Higher sustained caffeine exposure during the neonatal hospitalization is associated with improved neurodevelopmental outcomes in preterm infants.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Impact<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>Premature infants who receive caffeine for apnea of prematurity have improved neurodevelopmental outcomes compared to untreated infants.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The optimal dosing strategy for neuroprotection is unknown.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>We found that higher average daily exposure during the neonatal hospitalization was associated with reduced neurodevelopmental impairment at 30 months corrected age.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>High dose caffeine was associated with improved motor, language, and cognitive performance on the Bayley-III compared to low dose caffeine in multivariable analyses adjusted for gestational age and respiratory disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>Preterm infants may benefit from higher maintenance doses and\/or from continuing caffeine beyond the period of respiratory need.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41390-025-04387-1","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T16:51:47Z","timestamp":1758387107000},"page":"2605-2613","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cumulative caffeine exposure predicts neurodevelopmental outcomes in premature infants"],"prefix":"10.1038","volume":"99","author":[{"given":"Bridget E. L.","family":"Ostrem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Odell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly N.","family":"Grelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katelin","family":"Kramer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. James","family":"Barkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Barkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna M.","family":"Ferriero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn","family":"Gano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,20]]},"reference":[{"key":"4387_CR1","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1001\/jamapediatrics.2023.3487","volume":"177","author":"T Venkatesan","year":"2023","unstructured":"Venkatesan, T. et al. National trends in preterm infant mortality in the United States by race and socioeconomic status, 1995\u20132020. JAMA Pediatr. 177, 1085\u20131095 (2023).","journal-title":"JAMA Pediatr."},{"key":"4387_CR2","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1001\/jama.2021.23580","volume":"327","author":"EF Bell","year":"2022","unstructured":"Bell, E. F. et al. Mortality, in-hospital morbidity, care practices, and 2-year outcomes for extremely preterm infants in the US, 2013\u20132018. JAMA 327, 248\u2013263 (2022).","journal-title":"JAMA"},{"key":"4387_CR3","unstructured":"Behrman, R. E. & Butler, A. S. Outcomes I of M (US) C on UPB and AH. Neurodevelopmental, health, and family outcomes for infants born preterm. in: preterm birth: causes, consequences, and prevention. Natl. Acad. Press https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK11356\/ (2007)."},{"key":"4387_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1080\/87565641.2011.540538","volume":"36","author":"PJ Anderson","year":"2011","unstructured":"Anderson, P. J. et al. Attention problems in a representative sample of extremely preterm\/extremely low birth weight children. Dev. Neuropsychol. 36, 57\u201373 (2011).","journal-title":"Dev. Neuropsychol."},{"key":"4387_CR5","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.pediatrneurol.2023.08.001","volume":"148","author":"JB Russ","year":"2023","unstructured":"Russ, J. B. & Ostrem, B. E. L. Acquired brain injuries across the perinatal spectrum: pathophysiology and emerging therapies. Pediatr. Neurol. 148, 206\u2013214 (2023).","journal-title":"Pediatr. Neurol."},{"key":"4387_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1891\/0730-0832.35.2.73","volume":"35","author":"D Gano","year":"2016","unstructured":"Gano, D. White matter injury in premature newborns. Neonatal Netw. 35, 73\u201377 (2016).","journal-title":"Neonatal Netw."},{"key":"4387_CR7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.clp.2018.05.010","volume":"45","author":"A Leon Hernandez","year":"2018","unstructured":"Leon Hernandez, A. The impact of prematurity on social and emotional development. Clin. Perinatol. 45, 547\u2013555 (2018).","journal-title":"Clin. Perinatol."},{"key":"4387_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000528914","volume":"120","author":"DG Sweet","year":"2023","unstructured":"Sweet, D. G. et al. European consensus guidelines on the management of respiratory distress syndrome: 2022 update. Neonatology 120, 3\u201323 (2023).","journal-title":"Neonatology"},{"key":"4387_CR9","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa054065","volume":"354","author":"B Schmidt","year":"2006","unstructured":"Schmidt, B. et al. Caffeine therapy for apnea of prematurity. N. Engl. J. Med. 354, 2112\u20132121 (2006).","journal-title":"N. Engl. J. Med."},{"key":"4387_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1159\/000534497","volume":"121","author":"V Karlinski Vizentin","year":"2024","unstructured":"Karlinski Vizentin, V. et al. Early versus late caffeine therapy administration in preterm neonates: an updated systematic review and meta-analysis. Neonatology 121, 7\u201316 (2024).","journal-title":"Neonatology"},{"key":"4387_CR11","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa073679","volume":"357","author":"B Schmidt","year":"2007","unstructured":"Schmidt, B. et al. Long-term effects of caffeine therapy for apnea of prematurity. N. Engl. J. Med. 357, 1893\u20131902 (2007).","journal-title":"N. Engl. J. Med."},{"key":"4387_CR12","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.jpeds.2014.04.016","volume":"165","author":"LW Doyle","year":"2014","unstructured":"Doyle, L. W. et al. Reduction in developmental coordination disorder with neonatal caffeine therapy. J. Pediatr. 165, 356\u2013359.e2 (2014).","journal-title":"J. Pediatr."},{"key":"4387_CR13","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/jamapediatrics.2017.0238","volume":"171","author":"B Schmidt","year":"2017","unstructured":"Schmidt, B. et al. Academic performance, motor function, and behavior 11 years after neonatal caffeine citrate therapy for apnea of prematurity: an 11-year follow-up of the CAP randomized clinical trial. JAMA Pediatr. 171, 564\u2013572 (2017).","journal-title":"JAMA Pediatr."},{"key":"4387_CR14","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2017-4047","volume":"141","author":"IM M\u00fcrner-Lavanchy","year":"2018","unstructured":"M\u00fcrner-Lavanchy, I. M. et al. Neurobehavioral outcomes 11 years after neonatal caffeine therapy for apnea of prematurity. Pediatrics 141, e20174047 (2018).","journal-title":"Pediatrics"},{"key":"4387_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s41372-024-01939-x","volume":"44","author":"EA Oliphant","year":"2024","unstructured":"Oliphant, E. A., Hanning, S. M., McKinlay, C. J. D. & Alsweiler, J. M. Caffeine for apnea and prevention of neurodevelopmental impairment in preterm infants: systematic review and meta-analysis. J. Perinatol. 44, 785\u2013801 (2024).","journal-title":"J. Perinatol."},{"key":"4387_CR16","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1002\/ana.21008","volume":"60","author":"SA Back","year":"2006","unstructured":"Back, S. A. et al. Protective effects of caffeine on chronic hypoxia-induced perinatal white matter injury. Ann. Neurol. 60, 696\u2013705 (2006).","journal-title":"Ann. Neurol."},{"key":"4387_CR17","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1203\/PDR.0b013e31820efbcf","volume":"69","author":"SA Rivkees","year":"2011","unstructured":"Rivkees, S. A. & Wendler, C. C. Adverse and protective influences of adenosine on the newborn and embryo: implications for preterm white matter injury and embryo protection. Pediatr. Res. 69, 271\u2013278 (2011).","journal-title":"Pediatr. Res."},{"key":"4387_CR18","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41390-020-01162-2","volume":"90","author":"KN Grelli","year":"2021","unstructured":"Grelli, K. N. et al. Bronchopulmonary dysplasia precursors influence risk of white matter injury and adverse neurodevelopmental outcome in preterm infants. Pediatr. Res. 90, 359\u2013365 (2021).","journal-title":"Pediatr. Res."},{"key":"4387_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00000658-197801000-00001","volume":"187","author":"MJ Bell","year":"1978","unstructured":"Bell, M. J. et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann. Surg. 187, 1\u20137 (1978).","journal-title":"Ann. Surg."},{"key":"4387_CR20","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1164\/ajrccm.163.7.2011060","volume":"163","author":"AH Jobe","year":"2001","unstructured":"Jobe, A. H. & Bancalari, E. Bronchopulmonary dysplasia. Am. J. Respir. Crit. Care Med. 163, 1723\u20131729 (2001).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"4387_CR21","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jpeds.2016.06.079","volume":"177","author":"KC Wai","year":"2016","unstructured":"Wai, K. C. et al. Early cumulative supplemental oxygen predicts bronchopulmonary dysplasia in high risk extremely low gestational age newborns. J. Pediatr. 177, 97\u2013102.e2 (2016).","journal-title":"J. Pediatr."},{"key":"4387_CR22","doi-asserted-by":"crossref","unstructured":"Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics 105, 295\u2013310 (2000)","DOI":"10.1542\/peds.105.2.295"},{"key":"4387_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0022-3476(78)80282-0","volume":"92","author":"LA Papile","year":"1978","unstructured":"Papile, L. A., Burstein, J., Burstein, R. & Koffler, H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J. Pediatr. 92, 529\u2013534 (1978).","journal-title":"J. Pediatr."},{"key":"4387_CR24","first-page":"1661","volume":"24","author":"SP Miller","year":"2003","unstructured":"Miller, S. P. et al. Comparing the diagnosis of white matter injury in premature newborns with serial MR Imaging and transfontanel ultrasonography findings. AJNR Am. J. Neuroradiol. 24, 1661\u20131669 (2003).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"4387_CR25","doi-asserted-by":"crossref","unstructured":"Bayley, N. Bayley Scales of Infant and Toddler Development 3rd edn (Harcourt Assessment Inc., 2006).","DOI":"10.1037\/t14978-000"},{"key":"4387_CR26","doi-asserted-by":"publisher","first-page":"800","DOI":"10.3389\/fphys.2019.00800","volume":"10","author":"E Villamor-Martinez","year":"2019","unstructured":"Villamor-Martinez, E. et al. Cerebellar hemorrhage in preterm infants: a meta-analysis on risk factors and neurodevelopmental outcome. Front. Physiol. 10, 800 (2019).","journal-title":"Front. Physiol."},{"key":"4387_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2023.113488","volume":"259","author":"B Schmidt","year":"2023","unstructured":"Schmidt, B. Caffeine for apnea of prematurity: too much or too little of a good thing. J. Pediatr. 259, 113488 (2023).","journal-title":"J. Pediatr."},{"key":"4387_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.siny.2020.101178","volume":"25","author":"V Saroha","year":"2020","unstructured":"Saroha, V. & Patel, R. M. Caffeine for preterm infants: fixed standard dose, adjustments for age or high dose?. Semin. Fetal Neonatal Med. 25, 101178 (2020).","journal-title":"Semin. Fetal Neonatal Med."},{"key":"4387_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.724161","volume":"9","author":"L Yang","year":"2021","unstructured":"Yang, L. et al. Encephalopathy in preterm infants: advances in neuroprotection with caffeine. Front. Pediatr. 9, 724161 (2021).","journal-title":"Front. Pediatr."},{"key":"4387_CR30","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/archdischild-2022-324010","volume":"108","author":"EA Oliphant","year":"2023","unstructured":"Oliphant, E. A. et al. Caffeine to prevent intermittent hypoxaemia in late preterm infants: randomised controlled dosage trial. Arch. Dis. Child Fetal Neonatal Ed. 108, 106\u2013113 (2023).","journal-title":"Arch. Dis. Child Fetal Neonatal Ed."},{"key":"4387_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.resp.2020.103495","volume":"281","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. Early application of caffeine improves white matter development in very preterm infants. Respir. Physiol. Neurobiol. 281, 103495 (2020).","journal-title":"Respir. Physiol. Neurobiol."},{"key":"4387_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-36653-9","volume":"13","author":"H Sabir","year":"2023","unstructured":"Sabir, H. et al. Comparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia-ischemia in newborn rats: a multi-drug randomized controlled screening trial. Sci. Rep. 13, 9467 (2023).","journal-title":"Sci. Rep."},{"key":"4387_CR33","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1161\/STROKEAHA.124.048264","volume":"55","author":"JK Mike","year":"2024","unstructured":"Mike, J. K. et al. Perinatal caffeine administration improves outcomes in an ovine model of neonatal hypoxia-ischemia. Stroke 55, 2705\u20132715 (2024).","journal-title":"Stroke"},{"key":"4387_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jpeds.2014.09.009","volume":"166","author":"D Gano","year":"2015","unstructured":"Gano, D. et al. Diminished white matter injury over time in a cohort of premature newborns. J. Pediatr. 166, 39\u201343 (2015).","journal-title":"J. Pediatr."},{"key":"4387_CR35","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.3174\/ajnr.A3521","volume":"34","author":"H Kidokoro","year":"2013","unstructured":"Kidokoro, H., Neil, J. J. & Inder, T. E. New MR imaging assessment tool to define brain abnormalities in very preterm infants at term. AJNR Am. J. Neuroradiol. 34, 2208\u20132214 (2013).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"4387_CR36","doi-asserted-by":"publisher","first-page":"e0156245","DOI":"10.1371\/journal.pone.0156245","volume":"11","author":"M Martinez-Biarge","year":"2016","unstructured":"Martinez-Biarge, M. et al. MRI based preterm white matter injury classification: the importance of sequential imaging in determining severity of injury. PLoS ONE 11, e0156245 (2016).","journal-title":"PLoS ONE"},{"key":"4387_CR37","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.jpeds.2020.04.042","volume":"223","author":"AM Dylag","year":"2020","unstructured":"Dylag, A. M. et al. Early neonatal oxygen exposure predicts pulmonary morbidity and functional deficits at 1 year. J. Pediatr. 223, 20\u201328.e2 (2020).","journal-title":"J. Pediatr."},{"key":"4387_CR38","doi-asserted-by":"publisher","first-page":"e1258","DOI":"10.1542\/peds.2014-3039","volume":"135","author":"MM Spencer-Smith","year":"2015","unstructured":"Spencer-Smith, M. M. et al. Bayley-III cognitive and language scales in preterm children. Pediatrics 135, e1258\u2013e1265 (2015).","journal-title":"Pediatrics"},{"key":"4387_CR39","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1080\/13854046.2016.1216518","volume":"31","author":"PJ Anderson","year":"2017","unstructured":"Anderson, P. J. & Burnett, A. Assessing developmental delay in early childhood - concerns with the Bayley-III scales. Clin. Neuropsychol. 31, 371\u2013381 (2017).","journal-title":"Clin. Neuropsychol."},{"key":"4387_CR40","doi-asserted-by":"crossref","unstructured":"Odell, E. P. et al. Minimum effective dose of clemastine in a mouse model of preterm white matter injury. Pediatr. Res. 96, 933\u2013941 (2024)","DOI":"10.1038\/s41390-024-03326-w"},{"key":"4387_CR41","unstructured":"Ostrem B. E. L. & Gano D. Novel approaches to the treatment of preterm white matter injury through targeting remyelination. Clin. Perinatol. https:\/\/www.perinatology.theclinics.com\/article\/S0095-5108(25)00007-7\/abstract. (2025)."},{"key":"4387_CR42","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.3390\/antiox12081630","volume":"12","author":"S H\u00e4usler","year":"2023","unstructured":"H\u00e4usler, S. et al. Melatonin as a therapy for preterm brain injury: What is the evidence? Antioxidant 12, 1630 (2023).","journal-title":"Antioxidant"},{"key":"4387_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105492","volume":"111","author":"L Zhou","year":"2025","unstructured":"Zhou, L. et al. Feasibility and safety of autologous cord blood derived cell administration in extremely preterm infants: a single-centre, open-label, single-arm, phase I trial (CORD-SaFe study). EBioMedicine 111, 105492 (2025).","journal-title":"EBioMedicine"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04387-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04387-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:01:06Z","timestamp":1787047266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41390-025-04387-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,20]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["4387"],"URL":"https:\/\/doi.org\/10.1038\/s41390-025-04387-1","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,20]]},"assertion":[{"value":"17 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"Parental consent for subject participation was obtained for this study.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Ethics"}}]}}